Platelet alpha(2A)-adrenoceptor function in major depression: G(i) coupling, effects of imipramine and relationship to treatment outcome

Psychiatry Research

Volumn 89, Issue 2, 1999, Pages 73-95

  Gurguis, George N M ^a,b   Vo, Stephanie P ^b   Griffith, Jay M ^a   Rush, A John ^b  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Alpha(2A) adrenoceptors; Anxiety; Coupling; G(i) protein; Major depression; Platelets; Tricyclic antidepressants

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; IMIPRAMINE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN KINASE C; YOHIMBINE; ADRENERGIC RECEPTOR AFFECTING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; BIOLOGICAL MARKER; NORADRENALIN; PROTEIN KINASE; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; RECEPTOR DENSITY; REVIEW; THROMBOCYTE MEMBRANE; TREATMENT OUTCOME; ADULT; ARTICLE; BLOOD; CASE CONTROL STUDY; DRUG EFFECT; MAJOR DEPRESSION; METABOLISM; MIDDLE AGED; PROTEIN BINDING; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; THROMBOCYTE;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIOLOGICAL MARKERS; BLOOD PLATELETS; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HUMANS; IMIPRAMINE; MALE; MIDDLE AGED; NOREPINEPHRINE; PROTEIN BINDING; PROTEIN KINASES; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, ADRENERGIC, ALPHA-2; TREATMENT OUTCOME; YOHIMBINE;

EID: 0033589882     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(99)00103-1     Document Type: Article

References (138)

1. 2-adrenoceptor-mediated contractions of rabbit saphenous vein. European Journal of Pharmacology. 277:1995;35-44.
2. Aitken R.C.B. Measurement of feelings using visual analogue scales. Proceedings of the Royal Society of Medicine. 62:1969;989-993.
3. Aitken R.C.B., Gedye J.L. A study of two factors which affect arousal level and the apparent duration of a ten-minute interval. British Journal of Psychology. 59:1968;253-263.
4. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Press, Washington, DC.
5. Asakura M., Tsukamoto T., Hasegawa K. Modulation of rat brain alpha 2- and beta-adrenergic receptor sensitivity following long-term treatment with antidepressants. Brain Research. 235:1982;192-197.
6. 3H-Clonidine binding to membranes of platelets prepared under physiological conditions. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 9:1985;579-583.
7. 2-adrenergic receptor by the β-adrenergic receptor kinase. Journal of Biological Chemistry. 262:1987;17251-17253.
8. Bhatia S.C., Hsieh H.H., Theesen K.A., Townley R.G., Andersen J.M., Weiss S., Agrawal D.K. Platelet alpha-2 adrenoreceptor activity pre-treatment and post-treatment in major depressive disorder with melancholia. Research Communications in Chemical Pathology and Pharmacology. 74:1991;47-57.
9. Braddock L., Cowen P.J., Elliott J.M., Fraser S., Stump K. Binding of yohimbine and imipramine to platelets in depressive illness. Psychological Medicine. 16:1986;765-773.
10. Brunello N., Langer S.Z., Perez J., Racagni G. Current understanding of the mechanism of action of classic and new antidepressant drugs. Depression. 2:1995;119-126.
11. Butler J., O'Halloran A., Leonard B.E. The Galway study of panic disorder II: Changes in some peripheral markers of noradrenergic and serotonergic function in DSM III-R panic disorder. Journal of Affective Disorders. 26:1992;89-100.
12. 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Molecular Pharmacology. 42:1992;1-5.
13. 2 adrenoceptors and measurement in control and depressed subjects. Psychiatry Research. 14:1985;17-31.
14. 2-adrenoceptor levels on platelets of patients with major depressive disorders. Psychiatry Research. 18:1986;321-331.
15. 2-adrenoceptors accompanies reductions in yohimbine binding after clorgyline treatment. European Journal of Pharmacology. 81:1982;142-148.
16. Cooper S.J., Kelly J.G., King D.J. Adrenergic receptors in depression: effects of electroconvulsive therapy. British Journal of Psychiatry. 147:1985;23-29.
17. Corn T.H., Thompson C., Checkley S.A. Effects of desipramine treatment upon central adrenoceptor function in normal subjects. British Journal of Psychiatry. 145:1984;139-145.
18. Crews F.T., Smith C.B. Potentiation of responses to adrenergic nerve stimulation in isolated rat atria during chronic tricyclic antidepressant administration. Journal of Pharmacology and Experimental Therapeutics. 215:1980;143-149.
19. 3H-yohimbine affinity. Life Sciences. 29:1981;2059-2064.
20. DeLean A., Stadel J.M., Lefkowitz R.J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. Journal of Biological Chemistry. 255:1980;7108-7117.
21. DeLean A., Hancock A.A., Lefkowitz R.J. Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Molecular Pharmacology. 21:1982;5-16.
22. Doyle M.C., George A.J., Ravindran A.U., Philpott R. Platelet alpha-2-adrenergic receptor binding in elderly depressed patients. American Journal of Psychiatry. 142:1985;1489-1490.
23. 2A-adrenergic receptor. Journal of Biological Chemistry. 270:1995;4681-4688.
24. Elkin I., Shea T., Watkins J.T., Imber S.D., Sotsky S.M., Collins J.F., Glass D.R., Pilkonis P.A., Leber W.R., Docherty J.P., Fiester S.J., Parloff M.B. National Institute of Mental Health Treatment of Depression Collaborative Research Program. Archives of General Psychiatry. 46:1989;971-982.
25. Folstein M.F., Luria R. Reliability, validity, and clinical application of the visual analogue mood scale. Psychological Medicine. 3:1973;479-486.
26. i) in human platelets. FEBS Letters. 257:1989;427-430.
27. 2-adrenoceptor function in depression and response to drug treatment. Leonard B., Spencer P. Antidepressants: Thirty Years On. 1990;163-168 CNS (Clinical Neuroscience) Publishers, London.
28. 3H] yohimbine and competitive inhibition by antidepressant drugs. European Journal of Pharmacology. 74:1981;329-341.
29. 2-adrenergic receptors in major depressive disorder: binding of tritiated clonidine before and after tricyclic antidepressant drug treatment. Archives of General Psychiatry. 38:1981;1327-1333.
30. 2-adrenoreceptors on human platelet membranes. European Journal of Pharmacology. 69:1981;121-123.
31. 2-adrenoceptors in major affective disorder: effect of long-term lithium carbonate treatment. Archives of General Psychiatry. 43:1986;51-57.
32. 3H](-) adrenaline to platelets of depressed patients with melancholia: effect of long-term clomipramine treatment. Acta Psychiatrica Scandinavica. 75:1987;150-157.
33. 3H-imipramine binding in elderly depressed patients. Life Sciences. 40:1987;2137-2143.
34. 2-adrenoceptors after manipulation of noradrenergic transmission in the rat. European Journal of Pharmacology. 164:1989;455-466.
35. 2-adrenoceptor agonist binding sites in the hippocampus and frontal cortex of depressed suicide victims. Journal of Neurochemistry. 63:1994;256-265.
36. s protein in alcohol dependence, panic disorder, and patients with both conditions. Neuropsychopharmacology. 16:1997;69-76.
37. 2A receptors: implications for psychiatric research. Psychiatry Research. 80:1998;227-238.
38. i protein coupling, effects of imipramine and relationship to treatment outcome. Neuropsychopharmacology. 20:1999;162-176.
39. s protein coupling, effects of imipramine treatment and relationship to treatment outcome. Journal of Psychiatric Research. 33:1999;309-322.
40. 2-adrenergic receptors in healthy volunteers. Psychiatry Research. 85:1999;305-314.
41. s coupling, effects of imipramine and relationship to treatment outcome. European Journal of Pharmacology, in press.
42. Hadcock J.R., Malbon C.C. Agonist regulation of gene expression of adrenergic receptors and G proteins. Journal of Neurochemistry. 60:1993;1-9.
43. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology. 32:1959;50-55.
44. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of the Society for Clinical Psychology. 6:1967;278-296.
45. 2-adrenoceptor function in the brain: rapid down-regulation by sibutramine hydrochloride. Psychopharmacology. 103:1991;251-257.
46. 2-adrenoceptor desensitization by desipramine and ECS. British Journal of Pharmacology. 103:1991;1865-1870.
47. 2-adrenoceptor binding in normal subjects during desipramine administration and withdrawal. Neuropsychopharmacology. 4:1991;117-124.
48. Hoffman B.B., Michel T., Kilpatrick D.M., Lefkowitz R.J., Tolbert M.E.M., Gilman H., Fain J.N. Agonist versus antagonist binding to α-adrenergic receptors. Proceedings of the National Academy of Sciences. 77:1980;4569-4573.
49. 2-adrenergic receptors. Endocrinology. 110:1982;926-932.
50. 2-adrenoceptor sensitivity following chronic imipramine treatment in rats. European Journal of Pharmacology. 120:1986;275-283.
51. Jacobs K.H., Bauer S., Watanabe Y. Modulation of adenylate cyclase of human platelets by phorbol ester. Impairment of the hormone-sensitive inhibitory pathway. FEBS. 151:1985;425-430.
52. Jacobs K.H., Watanabe Y., Bauer S. Interactions between the hormone-sensitive adenylate cyclase system and the phosphoinositide-metabolizing pathway in human platelets. Journal of Cardiovascular Pharmacology. 8:1986;S61-S64.
53. 2-adrenergic receptor subtypes. Journal of Biological Chemistry. 271:1996;18082-18087.
54. Jiménez-Rivera C.A., Segarra O., Santacana G., Hoffman T., Savage D.D., Weiss G.K. Chronic imipramine treatment induces downregulation of alpha-2 receptors in rat's locus coeruleus and A2 region of the tractus solitarius. Life Sciences. 58:1996;287-294.
55. 2- and β-adrenoreceptor sensitivity. European Journal of Pharmacology. 67:1980;123-127.
56. 2-adrenergic receptors in depression. Archives of General Psychiatry. 43:1986;91-95.
57. Kaneko M., Kanno T., Honda K., Mashiko H., Oosuga N., Watanabe A., Kumashiro H. Platelet alpha-2 adrenergic receptor binding and plasma free 3-methoxy-4-hydroxyphenyl-ethylene glycol in depressed patients before and after treatment with mianserin. Neuropsychobiology. 25:1992;14-19.
58. Karege F., Bouvier P., Stepanian R., Gaillard J. Change in platelet GTP-binding in drug-free depressed patients. Human Psychopharmacology. 11:1996;115-121.
59. Katada T., Gilman A.G., Watanabe Y., Bauer S., Jakobs K.H. Protein kinase C phosphorylates the inhibitory guanine-nucleotide-binding regulatory component and apparently suppresses its function in hormonal inhibition of adenylate cyclase. FEBS. 151:1985;431-437.
60. 2-adrenoceptors in depression. Journal of Affective Disorders. 17:1989;219-228.
61. Keith R.A., Howe B.B., Salama A.I. Modulation of peripheral beta-1 and alpha-2 receptor sensitivities by the administration of the tricyclic antidepressant, imipramine, alone and in combination with alpha-2 antagonists to rats. Journal of Pharmacology and Experimental Therapeutics. 236:1986;356-363.
62. Kent R.S., DeLean A., Lefkowitz R.J. A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. Molecular Pharmacology. 17:1980;14-23.
63. 2-adrenergic agonist binding with guanine nucleotide regulatory proteins. Biochemistry. 26:1987;3664-3672.
64. Kocsis J.H., Frances A.J., Voss C., Mann J.J., Mason B.J., Sweeney J. Imipramine treatment for chronic depresssion. Archives of General Psychiatry. 45:1988;253-257.
65. 2-adrenoceptors in the locus coeruleus and its projection fields in rat brain determined by quantitative autoradiography. Neuropsychopharmacology. 8:1993;57-65.
66. Kumar R., Holian O., Cook B., Roshani P. Inhibition of rat brain protein kinase C by lipid soluable psychotropics. Neurochemical Research. 22:1997;1-10.
67. Lacroix D., Blier P., Curet O., de Montigny C. Effects of long-term desipramine administration on noradrenergic neurotransmission: electrophysiological studies in the rat brain. Journal of Pharmacology and Experimental Therapeutics. 257:1991;1081-1090.
68. 2-adrenergic receptor activity in clinical studies of depression. Usdin E., Goldstein M., Friedhoff A.J., Georgotas A. Frontiers in Neuropsychiatric Research. 1983;331-356 MacMillan Press, London.
69. 2A-adrenergic receptor by protein kinase c. Molecular Pharmacology. 54:1998;44-49.
70. 2-adrenergic receptor. Transactions of the Association of American Physicians. 104:1991;40-47.
71. 2 receptor classification. Molecular Pharmacology. 38:1990;599-603.
72. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with Folin phenol reagent. Journal of Biological Chemistry. 193:1951;265-275.
73. Luria R.E. The validity and reliability of the visual analogue mood scale. Journal of Psychiatric Research. 12:1975;51-57.
74. Mann C.D., Vu T.B., Hrdina P.D. Protein kinase C in rat brain cortex and hippocampus: effect of repeated administration of fluoxetine and desipramine. British Journal of Pharmacology. 115:1995;595-600.
75. Marjamaki A., Sato M., Bouet-Alard R., Yang Q., Limon-Boulez I., Legrand C., Lanier S.M. Factors determining the specificity of signal transduction by guanine nucleotide-binding protein-coupled receptors. Journal of Biological Chemistry. 272:1997;16466-16473.
76. 2-adrenoceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant desipramine. Journal of Neurochemistry. 71:1998;790-798.
77. 2-adrenoceptor density in the frontal cortex of depressed suicide victims. Journal of Neural Transmission. 70:1987;377-381.
78. 2-adrenoreceptors in the brain of suicide victims: increased receptor density associated with major depression. Biological Psychiatry. 31:1992;471-490.
79. 2-adrenoceptors mediating mydriasis in the rat. Naunyn-Schmiedeberg's Archives of Pharmacology. 341:1990;101-107.
80. Miyamoto S., Nakanishi J., Asakura M. Phosphoproteins involved in the mode of action of antidepressants and electroconvulsive shock: a possible role of cytoskeletal proteins. Japanese Journal of Psychiatry and Neurology. 47:1993;426-427.
81. 2-autoreceptor sensitivity. Progress in Neuropsychopharmacology and Biological Psychiatry. 18:1994;1063-1072.
82. Mori H., Mikuni M., Koyama T., Yamashita I. Epinephrine stimulates inositol phospholipid metabolism by activating alpha-2 adrenergic receptors in human platelets. Life Sciences. 44:1989;741-747.
83. Mori S., Zanardi R., Popoli M., Garbini S., Brunello N., Smeraldi E., Racagni G., Perez J. cAMP-dependent phosphorylation system after short and long-term administration of moclobmide. Journal of Psychiatric Research. 32:1998;111-115.
84. Morishita S., Watanabe S. Effect of the tricyclic antidepressant desipramine on protein kinase C in rat brain and rabbit platelets in vitro. Psychiatry and Clinical Neurosciences. 51:1997;249-252.
85. Munson R.J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand binding systems. Analytical Biochemistry. 197:1983;220-239.
86. Munson R.J., Rodbard D. Computerized analysis of ligand binding data: basic principles and recent development. Rodbard D., Fortig A. Computers in Endocrinology. 1984;117-145 Raven Press, New York.
87. Nestler E.J., Terwilliger R.Z., Duman R.S. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. Journal of Neurochemistry. 53:1989;1644-1647.
88. 2 adrenergic receptors: evidence for a precoupled receptor-guanine nucleotide protein complex. Biochemistry. 27:1988;2374-2384.
89. o) in desipramine-induced refractoriness of adenylate cyclase in cerebral cortices of rats. Journal of Neurochemistry. 51:1988;194-199.
90. Ordway G.A., Jaconetta S.M., Halaris A.E. Characterization of subtypes of alpha-2 adrenoceptors in the human brain. Journal of Pharmacology. 264:1993;967-976.
91. 3H-clonidine binding in the platelets of patients with depressive and schizophrenic disorders. Psychiatry Research. 28:1989;73-88.
92. Pandey G.N., Pandey S.C., Davies J.M. Peripheral adrenergic receptors in affective illness and schizophrenia. Pharmacology and Toxicology. 66:1990;13-36.
93. Perez J., Tinelli D., Brunello N., Racagni G. cAMP-dependent phosphorylation of soluable and crude microtubule fractions of rat cerebral cortex after prolonged desmethylimipramine treatment. European Journal of Pharmacology - Molecular Pharmacology Section. 172:1989;305-316.
94. Perez J., Tinelli D., Bianchi E., Brunello N., Racagni G. cAMP binding proteins in the rat cerebral cortex after adminstration of selective 5-HT and NE reuptake blockers with antidepressant activity. Neuropsychopharmacology. 4:1991;57-64.
95. Perez J., Tinelli D., Cagnoli C., Pecin P., Brunello N., Racagni G. Biochemical and molecular studies after long term administration of 5HT reuptake inhibitors: comparison with other antidepressants. Clinical Neuropharmacology. 15:1992;438A-439A.
96. 3H-para-aminoclonidine binding to platelet adrenoceptors in depression. Progress in Neuropsychopharmacology and Biological Psychiatry. 12:1988;541-553.
97. 2 adrenoreceptors in depressive illness. Life Sciences. 39:1986;1589-1616.
98. 3H-para-aminoclonidine binding to platelet purified plasma membranes from depressed patients. Neuropsychopharmacology. 3:1990;201-210.
99. Piletz J.E., Halaris A., Saran A., Marler M.R. Desipramine lowers tritiated para-aminoclonidine binding in platelets of depressed patients. Archives of General Psychiatry. 48:1991;813-820.
100. 2-adrenoceptor-mediated platelet aggregation in depressed patients. Neuropsychopharmacology. 9:1993;55-66.
101. 3H-Rauwolscine binding in platelets from depressed patients and healthy volunteers. Psychopharmacology. 79:1983;308-312.
102. 2+/calmodulin-dependent protein kinase II: autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin reuptake. Molecular Pharmacology. 48:1995;623-629.
103. Potter W.Z., Manji H.K. Catecholamines in depression: an update. Clinical Chemistry. 40:1994;279-287.
104. Racagni G., Brunello N., Tinelli D., Perez J. New biochemical hypotheses on the mechanism of action of antidepressant drugs: cAMP-dependent phosphorylation system. Pharmacopsychiatry. 25:1992;51-55.
105. 2-adrenoceptors in normotensive but not in spontaneously hypertensive rats. British Journal of Pharmacology. 110:1993;99-106.
106. Rickels K., Feighner J.P., Smith W.T. Alprazolam, amitripyline, doxepin, and placebo in the treatment of depression. Archives of General Psychiatry. 42:1985;134-141.
107. Rickels K., Chung H.R., Csanalosi I.B., Hurowitz A.M., London J., Wiseman K., Kaplan M., Amsterdam J.D. Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. Archives of General Psychiatry. 44:1987;862-866.
108. Sakaue M., Hoffman B.B. cAMP regulates transcription of the α2A adrenergic receptor gene in HT-29 cells. Journal of Biological Chemistry. 266:1991;5743-5749.
109. 2- and β-adrenergic receptors following repeated imipramine, yohimbine and electroconvulsive shock treatment to rats. Usdin E., Goldstein M., Friedhoff A.J., Georgotas A. Frontiers in Neuropsychiatric Research. 1982;145-158 MacMillan Press, New York.
110. Schittecatte M., Charles G., Nefve C., Valentin J.G., Machowski R., Wilmotte J. Long-term downregulation of central adrenoceptor function by desipramine treatment: a clonidine study in normal subjects. Biological Psychiatry. 31:1992;856-858.
111. Sekiya Y., Sugita R., Terada K., Sawa Y., Nomura S. Effects of desipramine and clomipramine on alpha 2-adrenergic receptor function in nucleus accumbens: studies with intracerabral dialysis in freely moving rats. Seishin Shinkeigaku Zasshi - Psychiatria et Neurologia Japonica. 97:1995;605-622.
112. Sevy S., Papadimitriou G.N., Surmont D.W., Goldman S., Mendlewicz J. Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Biological Psychiatry. 25:1989;141-152.
113. Siever L.J., Kafka M.S., Insel T.R., Lake C.R., Murphy D.L. Effect of long-term clorgyline administration on human platelet alpha-adrenergic receptor binding and platelet cyclic AMP responses. Psychiatry Research. 9:1983;37-44.
114. Siever L.J., Kafka M.S., Targum S., Lake C.R. Platelet alpha-adrenergic binding and biochemical responsiveness in depressed patients and controls. Psychiatry Research. 11:1984;287-302.
115. α C-terminal antibodies. Proceedings of the National Academy of Sciences. 86:1989;7809-7813.
116. 2 adrenoreceptors and the mechanism of action of tricyclic antidepressant drugs. Fleming W.W. Neuronal and Extraneuronal Events in Autonomic Pharmacology. 1984;181-192 Raven Press, New York.
117. 2 adrenoreceptors and antidepressant treatments. Szabadi E., Bradshaw C., Nahorski S.R. Pharmacology of Adrenoceptors. 1985;131-136 VCH, Deerfield, MI.
118. 2-Adrenoreceptors in rat brain are decreased after long-term tricyclic antidepressant drug treatment. Brain Research. 210:1981;413-418.
119. 2 adrenoreceptors are decreased in number after antidepressant therapy. Progress in Neuropsychopharmacology and Biological Psychiatry. 7:1983;241-247.
120. Spielberger C.D. Manual for the State-Trait Anxiety Inventory, Revised. 1983;Consulting Psychologists Press, Palo Alto, CA.
121. Spielberger C.D., Gorsuch R.L., Lushene R.E. STAI Manual for the State-Trait Anxiety Inventory (`Self-Evaluation Questionnaire'). 1970;Consulting Psychologists Press, Palo Alto, CA.
122. 2-adrenergic receptor sensitivity in major depressive disorder. Psychiatry Research. 10:1983;157-164.
123. Svensson T.H. Central alpha-adrenoceptors and the mechanisms of action of antidepressant drugs. Usdin E. Frontiers in Biochemical and Pharmacological Research in Depression. 1984;241-248 Raven Press, New York.
124. 1-adrenoceptor-induced translocation of protein kinase C in the central nervous system in rats. Pharmacological Research. 35:1997;569-576.
125. Tadokoro C., Kiuchi Y., Yamazaki Y., Oguchi K., Kamijima K. Effects of imipramine and sertraline on protein kinase activity in rat frontal cortex. European Journal of Pharmacology. 342:1998;51-54.
126. 3H-imipramine binding and plasma cortisol level in depression. Biological Psychiatry. 26:1989;52-60.
127. 3H]UK-14,304, in depressed patients and matched controls. European Journal of Pharmacology. 126:1986;329-332.
128. 2-adrenergic receptors after inactivation of Ni by pertussis toxin. Endocrinology. 119:1986;1305-1314.
129. 2-adrenergic receptor. Molecular Pharmacology. 34:1988;814-822.
130. Vaitla R., Roshani P., Holian O., Cook B., Kumar R. Inhibition of skin protein kinase C by psychotropic drugs. Skin Pharmacology. 10:1997;191-199.
131. 2-adrenergic receptors in depressed patients and healthy volunteers: the effects of desipramine. Pharmacopsychiatry. 25:1992;199-206.
132. Werstiuk E.S., Coote M., Griffith L., Shannon H., Steiner M. Effects of electroconvulsive therapy on peripheral adrenoceptors, plasma, noradrenaline, MHPG and cortisol in depressed patients. British Journal of Psychiatry. 169:1996;758-765.
133. Wirz-Justice A. Platelet research in psychiatry. Experientia. 44:1988;145-152.
134. 3H-yohimbine. Psychiatry Research. 20:1987;107-116.
135. 3H-yohimbine binding to platelet membranes and clonidine-induced hypotension. Biological Psychiatry. 25:1989;382-392.
136. Yoshioka M., Matsumoto M., Numazawa R., Togashi H., Smith C.B., Saito H. Changes in the regulation of 5-hydroxytryptamine release by (2-adrenoceptors in the rat hippocampus after long-term desipramine treatment. European Journal of Pharmacology. 294:1995;565-570.
137. Zealley A.K., Aitken R.C.B. Measurement of mood. Proceedings of the Royal Society of Medicine. 62:1969;993-996.
138. Zung W.W.K. A rating instrument for anxiety disorders. Psychosomatics. 12:1971;371-379.